Department of Neurosurgery, Wellington Regional Hospital, Wellington 6021, New Zealand.
Gillies McIndoe Research Institute, Wellington 6021, New Zealand.
Cells. 2019 Oct 31;8(11):1364. doi: 10.3390/cells8111364.
Patients with glioblastoma (GB), a highly aggressive brain tumor, have a median survival of 14.6 months following neurosurgical resection and adjuvant chemoradiotherapy. Quiescent GB cancer stem cells (CSCs) invariably cause local recurrence. These GB CSCs can be identified by embryonic stem cell markers, express components of the renin-angiotensin system (RAS) and are associated with circulating CSCs. Despite the presence of circulating CSCs, GB patients rarely develop distant metastasis outside the central nervous system. This paper reviews the current literature on GB growth inhibition in relation to CSCs, circulating CSCs, the RAS and the novel therapeutic approach by repurposing drugs that target the RAS to improve overall symptom-free survival and maintain quality of life.
胶质母细胞瘤（GB）是一种高度侵袭性的脑肿瘤，患者在神经外科切除和辅助放化疗后中位生存时间为 14.6 个月。静止的 GB 癌症干细胞（CSC）必然导致局部复发。这些 GB CSC 可以通过胚胎干细胞标志物来识别，表达肾素-血管紧张素系统（RAS）的组成部分，并与循环 CSC 相关。尽管存在循环 CSC，但 GB 患者很少在中枢神经系统外发生远处转移。本文综述了目前关于 CSC、循环 CSC、RAS 与 GB 生长抑制的文献，以及通过重新利用靶向 RAS 的药物来改善无进展总生存和维持生活质量的新治疗方法。
Zotero 插件